ストックスクリーナーアプリを入手
33.79
5.00%
1.61
アフターアワーズ：
33.79
前日終値:
$32.18
開ける：
$32.92
24時間の取引高:
1.04M
Relative Volume:
1.38
時価総額：
$2.00B
収益：
$205.63M
当期純損益:
$40.57M
株価収益率:
51.20
EPS:
0.6599
ネットキャッシュフロー:
$52.37M
1週間 パフォーマンス:
+8.93%
1か月 パフォーマンス:
-4.82%
6か月 パフォーマンス:
+47.23%
1年 パフォーマンス:
+336.56%
1日の値動き範囲:
$32.91
$34.93
1週間の範囲:
$29.86
$35.29
52週間の値動き範囲:
$5.35
$40.22
Stoke Therapeutics Inc Stock (STOK) Company Profile
Compare STOK vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
33.79 | 1.90B | 205.63M | 40.57M | 52.37M | 0.6599 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-24 | 開始されました | Wolfe Research | Outperform |
| 2026-02-05 | 開始されました | Guggenheim | Buy |
| 2026-01-05 | 再開されました | Chardan Capital Markets | Buy |
| 2025-07-18 | 開始されました | Jefferies | Buy |
| 2024-12-20 | 開始されました | Chardan Capital Markets | Buy |
| 2024-10-14 | 再開されました | Leerink Partners | Outperform |
| 2024-03-26 | アップグレード | TD Cowen | Market Perform → Outperform |
| 2023-11-20 | 再開されました | JP Morgan | Neutral |
| 2023-07-25 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2023-05-01 | アップグレード | BofA Securities | Underperform → Neutral |
| 2023-04-26 | 再開されました | Canaccord Genuity | Buy |
| 2023-01-06 | ダウングレード | BofA Securities | Buy → Underperform |
| 2022-10-24 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2022-01-31 | 開始されました | Jefferies | Buy |
| 2021-12-03 | 開始されました | BofA Securities | Buy |
| 2021-11-22 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-05-18 | 開始されました | UBS | Neutral |
| 2021-05-10 | アップグレード | Wedbush | Neutral → Outperform |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-02-10 | ダウングレード | Wedbush | Outperform → Neutral |
| 2020-12-15 | 再開されました | H.C. Wainwright | Buy |
| 2020-12-11 | 繰り返されました | Needham | Buy |
| 2020-10-23 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-09-29 | 再開されました | JP Morgan | Neutral |
| 2020-09-29 | 開始されました | Needham | Buy |
| 2019-12-18 | 開始されました | Wedbush | Outperform |
| 2019-11-12 | 開始されました | BTIG Research | Buy |
| 2019-10-25 | 開始されました | H.C. Wainwright | Buy |
| 2019-07-15 | 開始されました | Canaccord Genuity | Buy |
| 2019-07-15 | 開始されました | Cowen | Outperform |
| 2019-07-15 | 開始されました | Credit Suisse | Outperform |
| 2019-07-15 | 開始されました | JP Morgan | Overweight |
すべてを表示
Stoke Therapeutics Inc (STOK) 最新ニュース
Gains Recap: How does Stoke Therapeutics Inc score in quality rankings2026 Historical Comparison & Expert Curated Trade Setups - baoquankhu1.vn
Stoke Therapeutics Insider Sold Shares Worth $313,038, According to a Recent SEC Filing - marketscreener.com
Stoke Therapeutics (STOK) counsel sells 9,293 shares under 10b5-1 plan - Stock Titan
Stoke Therapeutics CMO Sells $457,000 in Stock Amid 300% Rally - Yahoo Finance
(STOK) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
FY2030 Earnings Estimate for STOK Issued By HC Wainwright - MarketBeat
Stoke Therapeutics Hits Day Low at $33.50 Amid Price Pressure - Markets Mojo
Stoke earnings loom as analysts bet big on Dravet therapy potential By Investing.com - Investing.com Australia
Stoke earnings loom as analysts bet big on Dravet therapy potential - Investing.com
Stoke Therapeutics (NASDAQ:STOK) Stock Rating Lowered by Wall Street Zen - MarketBeat
Form 144 STOKE THERAPEUTICS INC For: 20 March By Investing.com - Investing.com Canada
Form 144 STOKE THERAPEUTICS INC For: 20 March - Investing.com
Canaccord Genuity Group Forecasts Strong Price Appreciation for Stoke Therapeutics (NASDAQ:STOK) Stock - MarketBeat
Jonathan Allan plans sale of 9,293 RSUs at STOK (NASDAQ: STOK) - Stock Titan
Stoke Therapeutics stock price target raised to $60 by Canaccord on higher revenue assumptions - Investing.com Australia
Stoke Therapeutics Insider Sold Shares Worth $456,835, According to a Recent SEC Filing - marketscreener.com
Stoke Therapeutics Insider Sold Shares Worth $285,901, According to a Recent SEC Filing - marketscreener.com
Leggett, Stoke Therapeutics CFO, sells $147k in STOK stock By Investing.com - Investing.com Australia
Stoke Therapeutics’ chief medical officer Ticho sells shares worth $413k - Investing.com India
Allan, Jonathan, Stoke Therapeutics general counsel, sells $285k in STOK - Investing.com India
Barry Ticho Sells 1,461 Shares of Stoke Therapeutics (NASDAQ:STOK) Stock - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Insider Sells $58,790.81 in Stock - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Insider Sells $209,539.24 in Stock - MarketBeat
Insider Selling: Stoke Therapeutics (NASDAQ:STOK) CFO Sells 2,382 Shares of Stock - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) General Counsel Sells $145,041.52 in Stock - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) CFO Sells $72,489.96 in Stock - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) General Counsel Jonathan Allan Sells 4,267 Shares - MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Insider Barry Ticho Sells 6,164 Shares - MarketBeat
Leggett, Stoke Therapeutics CFO, sells $147k in STOK stock - Investing.com
Stoke Therapeutics (STOK) CMO sells 14,311 shares in planned trades - Stock Titan
Stoke Therapeutics (NASDAQ: STOK) CFO sells 4,578 shares to cover RSU tax - Stock Titan
Stoke Therapeutics (NASDAQ: STOK) officer sells 3,712 shares in tax-driven Form 4 - Stock Titan
Stoke Therapeutics (NASDAQ: STOK) counsel sells shares to cover tax withholding - Stock Titan
Stoke Therapeutics (NASDAQ:STOK) Stock Price Up 7.2%What's Next? - MarketBeat
Form 144: Morgan Stanley Smith Barney lists STOK resale of 1,365 shares (STOK) - Stock Titan
STOK: BTIG Reiterates Buy Rating with $39 Price Target | STOK St - GuruFocus
Stoke Therapeutics' (STOK) Buy Rating Reiterated at BTIG Research - MarketBeat
Guggenheim Remains a Buy on Stoke Therapeutics (STOK) - The Globe and Mail
Stoke Therapeutics earnings missed by $0.21, revenue fell short of estimates - Investing.com Canada
Stoke Therapeutics (NASDAQ: STOK) launches $150M ATM sales agreement with Cantor - Stock Titan
Stoke Therapeutics (STOK): Analyst Ratings and Price Target Upda - GuruFocus
Stoke Therapeutics (NASDAQ:STOK) Earns "Buy" Rating from Chardan Capital - MarketBeat
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Analysts Conflicted on These Healthcare Names: Stoke Therapeutics (STOK), NRX Pharmaceuticals (NRXP) and Airsculpt Technologies (AIRS) - The Globe and Mail
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)March 17, 2026 - BioSpace
Stoke Therapeutics (NASDAQ:STOK) What Triggered This Sudden Drop? - Kalkine Media
Stoke Therapeutics (STOK) Quarterly Losses Test Newly Profitable Trailing Earnings Narrative - simplywall.st
STOK: Wedbush Raises Price Target for Stoke Therapeutics | STOK Stock News - GuruFocus
Insider Selling: Stoke Therapeutics (NASDAQ:STOK) Director Sells 605 Shares of Stock - MarketBeat
Stoke Therapeutics (STOK) chief patient officer exercises 10,000 RSUs into shares - Stock Titan
Stoke Therapeutics (STOK) CFO exercises 14,750 RSUs, now holding 14,750 shares - Stock Titan
Stoke Therapeutics Inc (STOK) 財務データ
収益
当期純利益
現金流量
EPS
1.82%
大文字化:
|
ボリューム (24 時間):